Systematic Financial Management LP Decreases Stock Holdings in Integra LifeSciences Holdings Corporation $IART

Systematic Financial Management LP decreased its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 4.4% during the first quarter, Holdings Channel reports. The firm owned 1,059,286 shares of the life sciences company’s stock after selling 49,313 shares during the quarter. Systematic Financial Management LP’s holdings in Integra LifeSciences were worth $9,978,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Osaic Holdings Inc. grew its position in Integra LifeSciences by 36.6% in the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 1,104 shares during the period. State of Tennessee Department of Treasury lifted its holdings in shares of Integra LifeSciences by 7.9% during the 4th quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company’s stock valued at $332,000 after buying an additional 1,964 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Integra LifeSciences by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after buying an additional 1,975 shares during the period. Capital Fund Management S.A. boosted its stake in shares of Integra LifeSciences by 5.7% in the 3rd quarter. Capital Fund Management S.A. now owns 37,322 shares of the life sciences company’s stock worth $535,000 after buying an additional 1,997 shares during the last quarter. Finally, Global Retirement Partners LLC purchased a new position in shares of Integra LifeSciences in the 4th quarter worth $25,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Trading Up 6.6%

Shares of IART stock opened at $19.79 on Friday. Integra LifeSciences Holdings Corporation has a 1 year low of $8.70 and a 1 year high of $20.26. The firm has a fifty day moving average price of $17.39 and a 200-day moving average price of $13.31. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95. The company has a market cap of $1.54 billion, a price-to-earnings ratio of -3.06, a PEG ratio of 1.29 and a beta of 1.22.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The firm had revenue of $391.92 million during the quarter, compared to analyst estimates of $381.81 million. During the same period in the prior year, the business posted $0.41 EPS. Integra LifeSciences’s revenue was up 2.4% on a year-over-year basis. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, equities analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research report on Thursday, June 18th. BMO Capital Markets initiated coverage on Integra LifeSciences in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 target price on the stock. Weiss Ratings upgraded Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. Wells Fargo & Company upped their price target on shares of Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. Finally, Citigroup reaffirmed a “neutral” rating and set a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. One analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Reduce” and an average price target of $18.33.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.